Ruda M, Kann N, Gordon S, Bergman J, Nelson W, Agback P, Hagberg L, Koehler KF. (2005)
"Solid-phase synthesis of a 6-Phenylquinolin-2(1H)-one library directed toward nuclear hormone receptors".J Comb Chem. 2005 Jul-Aug;7(4):567-73.
Zhao C, Toresson G, Xu L, Koehler KF, Gustafsson JÅ, Dahlman-Wright K. (2005)
"Mouse estrogen receptor beta isoforms exhibit differences in ligand selectivity and coactivator recruitment". Biochemistry. 2005 Jun 7;44(22):7936-44.
Koehler KF, Helguero LA, Haldosen LA, Warner M, Gustafsson JÅ. (2005)
"Reflections on the discovery and significance of estrogen receptor beta". Endocr Rev. 2005 May;26(3):465-78. Epub 2005 Apr 27. Review.
Hedfors A, Appelqvist T, Carlsson B, Bladh LG, Litten C, Agback P, Grynfarb M, Koehler KF, Malm J. (2005) "Thyroid receptor ligands. 3. Design and synthesis of 3,5-dihalo-4-alkoxyphenylalkanoic acids as indirect antagonists of the thyroid hormone receptor".
J Med Chem. 2005 May 5;48(9):3114-7.
Carlsson P, Koehler KF, Nilsson L. (2005) "Glucocorticoid receptor point mutation V571M facilitates coactivator and ligand binding by structural rearrangement and stabilization".
Mol Endocrinol. 2005 Aug;19(8):1960-77. Epub 2005 Mar 17.
Nilsson S, Koehler KF. (2005) "Oestrogen receptors and selective oestrogen receptor modulators: molecular and cellular pharmacology".
Basic Clin Pharmacol Toxicol. 2005 Jan;96(1):15-25. Review.
Grover, G J, and Malm J (2005) "Selective thyroid hormone agonists: A strategy for treating metabolic syndrome". Drug Discovery Today, Therapeutic Strategies, 2005, 2, 137-142
Grover, G J, and Malm, J (2005) "Development of the Thyroid Hormone Receptor β-Subtype Agonist KB-141: A Strategy for Body Weight Reduction and Lipid-Lowering With Minimal Cardiovascular Effects". Cardiovasc Drug Rev., 2005, 23, 133-148.
Åsa Hedfors, Theresa Appelqvist, Bo Carlsson, Lars-Göran Bladh, Chris Litten, Peter Agback, Marlena Grynfarb, Konrad F. Koehler and Johan Malm (2005). "Thyroid Receptor Ligands. 3. Design and Synthesis of 3,5-Dihalo-4-alkoxyphenylalkanoic acids as Indirect Antagonists of the Thyroid Hormone Receptor". J. Med. Chem., 2005, 48, 3114-3117.
Joulia Smirnova, Lars Engman, Carl-Magnus Andersson and Johan Malm (2005) "An Organoiron Approach to Thyroid Hormone Analogues". J. Organomet. Chem., 2005, 690, 1784-1793.
Berkenstam, A. and Gustafsson J-Å (2005). "Nuclear receptors and their relevance to diseases related to lipid metabolism". Current Opinion in Pharmacology 5:171-176.
Berkenstam et al. (2004) "Convergence of lipid homeostatis through licer X and thyroid hormone receptors". Mechanisms of Ageing and Dev. 125 (2004) 707-717.
Hirschberg, D., Jägerbrink, T., Samskog, J., Gustafsson, M., Ståhlberg, M., Alvelius, G., Husman, B., Carlquist, M., Jörnvall, H., Bergman, T. (2004) "Detection of Phosphorylated Peptides in Proteomic Analyses using Microfluidic Compact Disk Technology". Analytical Chemistry 2004, 76, 5864-5871
Malm, J (2004). "Thyroid Hormone Ligands and Metabolic Diseases". Curr. Pharm. Design., 2004, 10, 3525-3532.
Malm, J (2004). "Therapeutic Thyroid Hormone Ligand Patents 1998-2003". Expert Opin. Ther. Patents, 2004, 14, 1169-1183.
Björnstrom, L. and M. Sjöberg (2004). "Estrogen receptor-dependent activation of AP-1 via non-genomic signalling." Nucl Recept 2(1): 3.
Hangeland, J. J., A. M. Doweyko, et al. (2004). "Thyroid receptor ligands. Part 2: Thyromimetics with improved selectivity for the thyroid hormone receptor beta. " Bioorg Med Chem Lett 14(13): 3549-53.
Meyerson, G., B. Carlsson, et al. (2004). Use of the mineralocorticoid receptor structure for the development of novel antagonists. Nuclear Receptors: Steroid Sisters, Keystone, Keystone symposia.
von Geldern, T. W., N. Tu, et al. (2004). "Liver-selective glucocorticoid antagonists: a novel treatment for type 2 diabetes." J Med Chem 47(17): 4213-30.
Färnegårdh, M., T. Bonn, et al. (2003). "The three-dimensional structure of the liver X receptor beta reveals a flexible ligand-binding pocket that can accommodate fundamentally different ligands." J Biol Chem 278(40): 38821-8.
Grover, G. J., K. Mellström, et al. (2003). "Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability." Proc Natl Acad Sci U S A 100(17): 10067-72.
Kauppi, B., C. Jakob, et al. (2003). "The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism.
" J Biol Chem 278(25): 22748-54.
Östlund, H., E. Keller, et al. (2003). "Estrogen receptor gene expression in relation to neuropsychiatric disorders." Ann N Y Acad Sci 1007: 54-63.
Ye, L., Y. L. Li, et al. (2003). "Thyroid receptor ligands. 1. Agonist ligands selective for the thyroid receptor beta1." J Med Chem 46(9): 1580-8.
Barkhem, T., L. A. Haldosen, et al. (2002). "pS2 Gene expression in HepG2 cells: complex regulation through crosstalk between the estrogen receptor alpha, an estrogen-responsive element, and the activator protein 1 response element. " Mol Pharmacol 61(6): 1273-83.
Barkhem, T., L. A. Haldosen, et al. (2002). "Transcriptional synergism on the pS2 gene promoter between a p160 coactivator and estrogen receptor-alpha depends on the coactivator subtype, the type of estrogen response element, and the promoter context." Mol Endocrinol 16(11): 2571-81.
Baxter, J. D., P. Goede, et al. (2002). "Structure-based design and synthesis of a thyroid hormone receptor (TR) antagonist." Endocrinology 143(2): 517-24.
Carlsson, B., B. N. Singh, et al. (2002). "Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone." J Med Chem 45(3): 623-30.
Nilsson, S. and J. Å. Gustafsson (2002). "Biological role of estrogen and estrogen receptors." Crit Rev Biochem Mol Biol 37(1): 1-28.
Nilsson, S. and J. Å. Gustafsson (2002). "Estrogen receptor
action." Crit Rev Eukaryot Gene Expr 12(4): 237-57.
Nilsson, S. and J.-Å. Gustafsson (2002). Structure and function of the estrogen receptor. Contemporary endocrinology: Selective estrogen receptor modulators: Research and clinical applications. A. Manni and M. F. Verderame. Totowa, NJ, Humana press.
Wilkinson, H. A., J. Dahllund, et al. (2002). "Identification and characterization of a functionally distinct form of human estrogen receptor beta." Endocrinology 143(4): 1558-61.
Bian, Z., S. Nilsson, et al. (2001). "Selective estrogen receptor modulators
and coronary heart disease." Trends Cardiovasc Med 11(5): 196-202.
Nilsson, S., S. Mäkelä, et al. (2001). "Mechanisms of estrogen action.
" Physiol Rev 81(4): 1535-65.
Österlund, M. K. and Y. L. Hurd (2001). "Estrogen receptors in the human
forebrain and the relation to neuropsychiatric
disorders." Prog Neurobiol 64(3): 251-67.
Pike, A. C., A. M. Brzozowski, et al. (2001). "Structural insights into the
mode of action of a pure antiestrogen." Structure (Camb) 9(2): 145-53.
Weihua, Z., S. Makela, et al. (2001). "A role for estrogen receptor beta in the
regulation of growth of the ventral prostate." Proc Natl Acad Sci U S A 98(11): 6330-5.
Grön, H. and R. Hyde-DeRuyscher (2000). "Peptides as tools in drug discovery." Current Opinions in Drug Discovery 3(5): 636-645.
Hubbard, R. E., A. C. Pike, et al. (2000). "Structural insights into the mechanisms of agonism and antagonism in oestrogen receptor isoforms." Eur J Cancer 36 Suppl 4: S17-8.
Johansson, L., A. Bavner, et al. (2000). "The orphan nuclear receptor SHP utilizes conserved LXXLL-related motifs for interactions with ligand-activated estrogen receptors." Mol Cell Biol 20(4): 1124-33.
Nilsson, S. and J. Å. Gustafsson (2000). "Estrogen receptor transcription and transactivation: Basic aspects of estrogen action." Breast Cancer Res 2(5): 360-6.
Pike, A. C., A. M. Brzozowski, et al. (2000). "Structural aspects of agonism and antagonism in the oestrogen receptor." Biochem Soc Trans 28(4): 396-400.
Saji, S., E. V. Jensen, et al. (2000). "Estrogen receptors alpha and beta in the rodent mammary gland." Proc Natl Acad Sci U S A 97(1): 337-42.